Tanabe ALS

Objective

A Phase 3, Multi-center, Open-Label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS). The main purpose of this Research Study is to test whether an experimental drug called edaravone is safe and well tolerated in patients with your illness.

View this clinical trail on ClinicalTrials.gov.

Location:

Essentia Health East

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 02/18/2020

Research Study Categories

  • Adult Studies

Specialty

  • Neurology
Contact
Cardiology Clinical Trials at 866-839-4128
or clinicaltrials@essentiahealth.org